The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration

Neuron

Volumn 52, Issue 1, 2006, Pages 61-76

  Hauser, Stephen L ^a   Oksenberg, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMPA RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA INTERFERON; CYCLOPHOSPHAMIDE; DIZOCILPINE; DNA VACCINE; GEMFIBROZIL; GLATIRAMER; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 4; LENERCEPT; MYELIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NATALIZUMAB; NERVE GROWTH FACTOR; OKT 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHOSPHODIESTERASE IV INHIBITOR; RITUXIMAB; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANILAST; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

ANTIBODY RESPONSE; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DEMYELINATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; FLU LIKE SYNDROME; GENE IDENTIFICATION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MENSTRUATION DISORDER; MOLECULAR GENETICS; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NERVE FIBER REGENERATION; NEUROBIOLOGY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMYELINIZATION; REVIEW; RISK ASSESSMENT; SKIN MANIFESTATION; SPASTICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 6; DISEASE SUSCEPTIBILITY; GENETICS; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROBIOLOGY;

EID: 33749059726     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2006.09.011     Document Type: Review

References (159)

1. Acar G., Idiman F., Idiman E., Kirkali G., Cakmakci H., and Ozakbas S. Nitric oxide as an activity marker in multiple sclerosis. J. Neurol. 250 (2003) 588-592
2. Arnett H.A., Fancy S.P., Alberta J.A., Zhao C., Plant S.R., Kaing S., Raine C.S., Rowitch D.H., Franklin R.J., and Stiles C.D. bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 306 (2004) 2111-2115
3. Ascherio A., Munger K.L., Lennette E.T., Spiegelman D., Hernan M.A., Olek M.J., Hankinson S.E., and Hunter D.J. Epstein-Barr Virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286 (2001) 3083-3088
4. Bachelin C., Lachapelle F., Girard C., Moissonnier P., Serguera-Lagache C., Mallet J., Fontaine D., Chojnowski A., Le Guern E., Nait-Oumesmar B., and Baron-Van Evercooren A. Efficient myelin repair in the macaque spinal cord by autologous grafts of Schwann cells. Brain 128 (2005) 540-549
5. Bagnato F., Jeffreys N., Richert N.D., Stone R.D., Ohayon J.M., McFarland H.F., and Frank J.A. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 126 (2003) 1782-1789
6. Baranzini S.E., Jeong M.C., Butunoi C., Murray R.S., Bernard C.C., and Oksenberg J.R. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. 163 (1999) 5133-5144
7. Baranzini S.E., Mousavi P., Rio J., Caillier S.J., Stillman A., Villoslada P., Wyatt M.M., Comabella M., Greller L.D., Somogyi R., et al. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol. 3 (2005) e2 10.1371/journal.pbio.0030002
8. Barcellos L.F., Oksenberg J.R., Green A.J., Bucher P., Rimmler J.B., Schmidt S., Garcia M.E., Lincoln R.R., Pericak-Vance M.A., Haines J.L., and Hauser S.L. Genetic basis for clinical expression in multiple sclerosis. Brain 125 (2002) 150-158
9. Barcellos L.F., Oksenberg J.R., Begovich A.B., Martin E.R., Schmidt S., Vittinghoff E., Goodin D.S., Pelletier D., Lincoln R.R., Bucher P., et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 72 (2003) 710-716
10. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., Cree B.C., Begovich A.B., Villoslada P., Montalban X., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum. Mol. Genet. 15 (2006) 2813-2824
11. Barnett M.H., and Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55 (2004) 458-468
12. Bechtold D.A., Kapoor R., and Smith K.J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann. Neurol. 55 (2004) 607-616
13. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., and Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector T(H)17 and regulatory T cells. Nature 441 (2006) 235-238
14. Bezzi P., Domercq M., Brambilla L., Galli R., Schols D., De Clercq E., Vescovi A., Bagetta G., Kollias G., Meldolesi J., and Volterra A. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci. 4 (2001) 702-710
15. Bezzi P., Gundersen V., Galbete J.L., Seifert G., Steinhauser C., Pilati E., and Volterra A. Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. Nat. Neurosci. 7 (2004) 613-620
16. Bieber A.J., Kerr S., and Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann. Neurol. 53 (2003) 680-684
17. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., and Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123 (2000) 1174-1183
18. Bjartmar C., Kidd G., Mork S., Rudick R., and Trapp B.D. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48 (2000) 893-901
19. Bo L., Vedeler C.A., Nyland H.I., Trapp B.D., and Mork S.J. Supial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 62 (2003) 723-732
20. Bozzali M., Cergignami M., Sormani M.P., Comi G., and Filippi M. Quantification of brain grey matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am. J. Neuroradiol. 23 (2002) 985-988
21. Brassat D., Azais-Vuillemin C., Yaouanq J., Semana G., Reboul J., Cournu I., Mertens C., Edan G., Lyon-Caen O., Clanet M., and Fontaine B. Familial factors influence disability in MS multiplex families. Neurology 52 (1999) 1632-1636
22. Brex P.A., Ciccarelli O., O'Riordan J.I., Sailer M., Thompson A.J., and Miller D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346 (2002) 158-164
23. Brownell B., and Hughes J.T. The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 25 (1962) 315-320
24. Cader S., Cifeli A., Abu-Omar Y., Palace J., and Matthews P.M. Reduced brain functional reserve and altered functional connectivity in patients with multiple sclerosis. Brain 129 (2006) 527-537
25. Carrel L., and Willard H.F. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434 (2005) 400-404
26. Cepok S., Zhou D., Srivastava R., Nessler S., Stei S., Bussow K., Sommer N., and Hemmer B. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 115 (2005) 1352-1360
27. Chang A., Nishiyama A., Peterson J., Prineas J., and Trapp B.D. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J. Neurosci. 20 (2000) 6404-6412
28. Charles P., Hernandez M.P., Stankoff B., Aigrot M.S., Colin C., Rougon G., Zalc B., and Lubetzki C. Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc. Natl. Acad. Sci. USA 97 (2000) 7585-7590
29. Cid C., Alcazar A., Regidor I., Masjuan J., Salinas M., and Alvarez-Cermeno J.C. Neuronal apoptosis induced by cerebrospinal fluid from multiple sclerosis patients correlates with hypointense lesions on T1 magnetic resonance imaging. J. Neurol. Sci. 193 (2002) 103-109
30. Coles A.J., Cox A., Le Page E., Jones J., Trip S.A., Deans J., Seaman S., Miller D.H., Hale G., Waldmann H., and Compston D.A. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253 (2006) 98-108 10.1007/s00415-005-0934-5 Published online July 27, 2005
31. Colombo M., Dono M., Gazzola P., Roncella S., Valetto A., Chiorazzi N., Mancardi G.L., and Ferrarini M. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 164 (2000) 2782-2789
32. Compston A., Confavreux C., Lassmann H., McDonald I., Miller D., Noseworthy J., Smith K., and Wekerle H. McAlpine's Multiple Sclerosis. Fourth Edition (2006), Churchill Livingstone, Edinburgh
33. Confavreux C., and Vukusic S. Age at disability milestones in multiple sclerosis. Brain 129 (2006) 595-605
34. Confavreux C., and Vukusic S. Natural history of multiple sclerosis. A unifying concept. Brain 129 (2006) 561-563
35. Confavreux C., Vukusic S., and Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126 (2003) 770-782
36. Corcione A., Casazza S., Ferretti E., Giunti D., Zappia E., Pistorio A., Gambini C., Mancardi G.L., Uccelli A., and Pistoia V. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA 101 (2004) 11064-11069
37. Craner M.J., Hains B.C., Lo A.C., Black J.A., and Waxman S.G. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 127 (2004) 294-303
38. Cree B.A., Khan O., Bourdette D., Goodin D.S., Cohen J.A., Marrie R.A., Glidden D., Weinstock-Guttman B., Reich D., Patterson N., et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 63 (2004) 2039-2045
39. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., and Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 (2005) 1270-1272
40. Cross A.H., Misko T.P., Lin R.F., Hickey W.F., Trotter J.L., and Tilton R.G. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J. Clin. Invest. 93 (1994) 2684-2690
41. Cross A.H., and Stark J.L. Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Immunol. Res. 32 (2005) 85-98
42. Diemel L.T., Wolswijk G., Jackson S.J., and Cuzner M.L. Remyelination of cytokine- or antibody-demyelinated CNS aggregate cultures is inhibited by macrophage supplementation. Glia 45 (2004) 278-286
43. Dubois-Dalcq M., Ffrench-Constant C., and Franklin R.J. Enhancing central nervous system remyelination in multiple sclerosis. Neuron 48 (2005) 9-12
44. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59 (2006) 478-489
45. Dyment D.A., Herrera B.M., Cader M.Z., Willer C.J., Lincoln M.R., Sadovnick A.D., Risch N., and Ebers G.C. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum. Mol. Genet. 14 (2005) 2019-2026
46. Ebers G.C., Sadovnick A.D., and Risch N.J. A genetic basis for familial aggregation in multiple sclerosis. Nature 377 (1995) 150-151
47. Ebers G.C., Yee I.M., Sadovnick A.D., and Duquette P. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Ann. Neurol. 48 (2000) 927-931
48. Farina C., Weber M.S., Meinl E., Wekerle H., and Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 4 (2005) 567-575
49. Feldmann M., and Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 435 (2005) 612-619
50. Ferguson B., Matyszak M.K., Esiri M.M., and Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 120 (1997) 393-399
51. Filippi M., and Rocca M.A. MRI-clinical correlations in multiple sclerosis: implications for our understanding of neuronal changes. In: Waxman S. (Ed). Multiple Sclerosis as a Neuronal Disease (2005), Elsevier Academic Press, Amsterdam 215-225
52. Firth D. The case of Augustus D'Este (1948), Cambridge University Press, Cambridge
53. Foote A.K., and Blakemore W.F. Inflammation stimulates remyelination in areas of chronic demyelination. Brain 128 (2005) 528-539
54. Fredman D., White S.J., Potter S., Eichler E.E., Den Dunnen J.T., and Brookes A.J. Complex SNP-related sequence variation in segmental genome duplications. Nat. Genet. 36 (2004) 861-866
55. Frost E.E., Nielsen J.A., Le T.Q., and Armstrong R.C. PDGF and FGF2 regulate oligodendrocyte progenitor responses to demyelination. J. Neurobiol. 54 (2003) 457-472
56. Gadea M., Martinez-Bisbal M.C., Marti-Bonmati L., Espert R., Casanova B., Coret F., and Celda B. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain 127 (2004) 89-98
57. Garbern J.Y., Yool D.A., Moore G.J., Wilds I.B., Faulk M.W., Klugmann M., Nave K.A., Sistermans E.A., van der Knaap M.S., Bird T.D., et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 125 (2002) 551-561
58. Genain C.P., Lee-Paritz D., Nguyen M.-H., Massacesi L., Joshi N., Ferrante R., Hoffman K., Moseley M., Letvin N.L., and Hauser S.L. In healthy primates, circulating autoreactive T cells mediate autoimmune disease. J. Clin. Invest. 94 (1994) 1339-1345
59. Genain C.P., Cannella B., Hauser S.L., and Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5 (1999) 170-175
60. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., Vyhnalek P., Zadorova Z., Palmer T., and Donoghue S. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348 (2003) 24-32
61. Goodin D.S. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?. Ann. Neurol. 59 (2006) 597-605
62. Goodnow C.C., Sprent J., de St Groth B.F., and Vinuesa C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435 (2005) 590-597
63. Griffiths I., Klugmann M., Anderson T., Yool D., Thomson C., Schwab M.H., Schneider A., Zimmermann F., McCulloch M., Nadon N., and Nave K.A. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280 (1998) 1610-1613
64. Hafler D.A., Slavik J.M., Anderson D.E., O'Connor K.C., De Jager P., and Baecher-Allan C. Multiple sclerosis. Immunol. Rev. 204 (2005) 208-231
65. Haines J.L., Haines J.L., Terwedow H.A., Burgess K., Pericak-Vance M.A., Rimmler J.B., Martin E.R., Oksenberg J.R., Lincoln R., Zhang D.Y., et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum. Mol. Genet. 7 (1998) 1229-1234
66. Hauser S.L., and Goodin D.S. Multiple sclerosis and other demyelinating diseases. In: Kasper D.L., Braunwald E., Fauci A.D., Hauser S.L., Longo D.L., and Jameson J.L. (Eds). Harrison's Principle of Internal Medicine. Sixteenth Edition (2005), McGraw Hill, New York 2461-2471
67. Hoftberger R., Aboul-Enein F., Brueck W., Lucchinetti C., Rodriguez M., Schmidbauer M., Jellinger K., and Lassmann H. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 14 (2004) 43-50
68. Hohlfeld R., and Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. USA 101 Suppl 2 (2004) 14599-14606
69. Hohlfeld R., Kerschensteiner M., Stadelmann C., Lassmann H., and Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J. Neuroimmunol. 107 (2000) 161-166
70. Iafrate A.J., Feuk L., Rivera M.N., Listewnik M.L., Donahoe P.K., Qi Y., Scherer S.W., and Lee C. Detection of large-scale variation in the human genome. Nat. Genet. 36 (2004) 949-951
71. Kantarci O.H., de Andrade M., and Weinshenker B.G. Identifying disease modifying genes in multiple sclerosis. J. Neuroimmunol. 123 (2002) 144-159
72. Karadottir R., Cavelier P., Bergersen L.H., and Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 438 (2005) 1162-1166
73. Kerschensteiner M., Bareyre F.M., Buddeberg B.S., Merkler D., Stadelmann C., Bruck W., Misgeld T., and Schwab M.E. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J. Exp. Med. 200 (2004) 1027-1038
74. Kidd T., Barkhof F., McConnell R., Algra P.R., Allen I.V., and Revesz T. Cortical lesions in multiple sclerosis. Brain 122 (1999) 17-26
75. Kornek B., and Lassmann H. Axonal pathology in multiple sclerosis. A historical note. Brain Pathol. 9 (1999) 651-656
76. Kornek B., Storch M.K., Weissert R., Wallstroem E., Stefferl A., Olsson T., Linington C., Schmidbauer M., and Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157 (2000) 267-276
77. Kotter M.R., Zhao C., van Rooijen N., and Franklin R.J. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol. Dis. 18 (2005) 166-175
78. Krumbholz M., Theil D., Derfuss T., Rosenwald A., Schrader F., Monoranu C.M., Kalled S.L., Hess D.M., Serafini B., Aloisi F., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201 (2005) 195-200
79. Kurtzke J.F., Beebe G.W., and Norman Jr. J.E. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 29 (1979) 1228-1235
80. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Bruck W., Rauschka H., Bergmann M., Schmidbauer M., Parisi J.E., and Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 (2005) 2705-2712
81. Lang H.L., Jacobsen H., Ikemizu S., Andersson C., Harlos K., Madsen L., Hjorth P., Sondergaard L., Svejgaard A., Wucherpfennig K., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3 (2002) 940-943
82. Lappe-Siefke C., Goebbels S., Gravel M., Nicksch E., Lee J., Braun P.E., Griffiths I.R., and Nave K.A. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet. 33 (2003) 366-374
83. Lassmann H. Brain damage when multiple sclerosis is diagnosed clinically. Lancet 361 (2003) 1317-1318
84. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., and Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202 (2005) 473-477
85. Leppert D., Waubant E., Burk M.R., Oksenberg J.R., and Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40 (1996) 846-852
86. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K.M., Hauser S.L., and Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121 (1998) 2327-2334
87. Levin L.I., Munger K.L., Rubertone M.V., Peck C.A., Lennette E.T., Spiegelman D., and Ascherio A. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293 (2005) 2496-2500
88. Li C., Tropak M.B., Gerial R., Clapoff S., Abramov-Newerly W., Trapp B., Peterson A., and Roder J. Myelination in the absence of myelin-associated glycoprotein. Nature 369 (1994) 747-750
89. Lincoln M.R., Montpetit A., Cader M.Z., Saarela J., Dyment D.A., Tiislar M., Ferretti V., Tienari P.J., Sadovnick A.D., Peltonen L., et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat. Genet. 37 (2005) 1108-1112
90. Lindsey J.W., Hodgkinson S., Mehta R., Mitchell D., Enzmann D., and Steinman L. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol. 36 (1994) 183-189
91. Liu Y., Teige I., Birnir B., and Issazadeh-Navikas S. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat. Med. 12 (2006) 518-525
92. Lo A.C., Saab C.Y., Black J.A., and Waxman S.G. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J. Neurophysiol. 90 (2003) 3566-3571
93. Lo H.S., Wang Z., Hu Y., Yang H.H., Gere S., Buetow K.H., and Lee M.P. Allelic variation in gene expression is common in the human genome. Genome Res. 13 (2003) 1855-1862
94. Losseff N.A., Wang L., Lai H.M., Yoo D.S., Gawne-Cain M.L., McDonald W.I., Miller D.H., and Thompson A.J. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119 (1996) 2009-2019
95. Lucchinetti C.F., Bruck W., and Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann. Neurol. 56 (2004) 308
96. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., Hatton R.D., Wahl S.M., Schoeb T.R., and Weaver C.T. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441 (2006) 231-234
97. Mason J.L., Suzuki K., Chaplin D.D., and Matsushima G.K. Interleukin-1beta promotes repair of the CNS. J. Neurosci. 21 (2001) 7046-7052
98. th century?. Acta Neurol. Scand. 60 (1979) 189-192
99. Merkler D., Ernsting T., Kerschensteiner M., Bruck W., and Stadelmann C. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 129 (2006) 1979-1983
100. Miller D.H., Barkhof F., Frank J.A., Parker G.J., and Thompson A.J. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125 (2002) 1676-1695
101. Miretti M.M., Walsh E.C., Ke X., Delgado M., Griffiths M., Hunt S., Morrison J., Whittaker P., Lander E.S., Cardon L.R., et al. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 76 (2005) 634-646
102. Mummert S.K., Lobanenkov V.A., and Feinberg A.P. Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 43 (2005) 155-161
103. Neumann H. Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Curr. Opin. Neurol. 16 (2003) 267-273
104. Newman T.A., Woolley S.T., Hughes P.M., Sibson N.R., Anthony D.C., and Perry V.H. T-cell- and macrophage-mediated axon damage in the absence of a CNS- specific immune response: involvement of metalloproteinases. Brain 124 (2001) 2203-2214
105. Noseworthy J.H. Management of multiple sclerosis: current trials and future options. Curr. Opin. Neurol. 16 (2003) 289-297
106. O'Connor K.C., Appel H., Bregoli L., Call M.E., Catz I., Chan J.A., Moore N.H., Warren K.G., Wong S.J., Hafler D.A., and Wucherpfennig K.W. Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein. J. Immunol. 175 (2005) 1974-1982
107. O'Connor P.W., Goodman A., Willmer-Hulme A.J., Libonati M.A., Metz L., Murray R.S., Sheremata W.A., Vollmer T.L., and Stone L.A. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62 (2004) 2038-2043
108. Oksenberg J.R., and Barcellos L.F. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun. 6 (2005) 375-387
109. Oksenberg J.R., Barcellos L.F., Cree B.A., Baranzini S.E., Bugawan T.L., Khan O., Lincoln R.R., Swerdlin A., Mignot E., Lin L., et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am. J. Hum. Genet. 74 (2004) 160-167
110. Owens G.P., Kraus H., Burgoon M.P., Smith-Jensen T., Devlin M.E., and Gilden D.H. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann. Neurol. 43 (1998) 236-243
111. Pagani E., Filippi M., Rocca M.A., and Horsfield M.A. A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 26 (2005) 258-265
112. Patterson N., Hattangadi N., Lane B., Lohmueller K.E., Hafler D.A., Oksenberg J.R., Hauser S.L., Smith M.W., O'Brien S.J., Altshuler D., et al. Methods for high-density admixture mapping of disease genes. Am. J. Hum. Genet. 74 (2004) 979-1000
113. Peterson J.W., Bo L., Mork S., Chang A., and Trapp B.D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50 (2001) 389-400
114. Peterson J.W., Kidd G.J., and Trapp B.D. Axonal degeneration in MS: the histopathological evidence. In: Waxman S. (Ed). Multiple Sclerosis as a Neuronal Disease (2005), Elsevier Academic Press, Amsterdam 165-184
115. Platten M., and Steinman L. Multiple sclerosis: trapped in deadly glue. Nat. Med. 11 (2005) 252-253
116. Platten M., Ho P.P., Youssef S., Fontoura P., Garren H., Hur E.M., Gupta R., Lee L.Y., Kidd B.A., Robinson W.H., et al. Treatment of autoimmune neuroinflammation with synthetic tryptophan metabolite. Science 310 (2005) 850-855
117. Pluchino S., Zanotti L., Rossi B., Brambilla E., Ottoboni L., Salani G., Martinello M., Cattalini A., Bergami A., Furlan R., et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 436 (2005) 266-271
118. Poser C.M. The dissemination of multiple sclerosis: a Viking saga? A historical essay. Ann. Neurol. 36 (1994) S231-S243
119. Ransohoff R.M. Natalizumab and PML. Nat. Neurosci. 8 (2005) 1275
120. Redford E.J., Kapoor R., and Smith J.K. Nitric oxide donors reversibly block axonal conduction. Demyelinated axons are especially susceptible. Brain 120 (1997) 2149-2157
121. Reich D., Patterson N., De Jager P.L., McDonald G.J., Waliszewska A., Tandon A., Lincoln R.R., DeLoa C., Fruhan S.A., Cabre P., et al. A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nat. Genet. 37 (2005) 1113-1118
122. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am. J. Hum. Genet. 46 (1990) 222-228
123. Rivers T.M., and Schwenker F.F. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J. Exp. Med. 61 (1935) 689-702
124. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 22 (2001) 117-139
125. Rudick R.A., Lee J.C., Simon J., and Fisher E. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann. Neurol. (2006) in press
126. Sadovnick A.D., Ebers G.C., Dyment D.A., and Risch N.J. Evidence for genetic basis of multiple sclerosis. Lancet 347 (1996) 1728-1730
127. Sahrbacher U.C., Lechner F., Eugster H.P., Frei K., Lassmann H., and Fontana A. Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. Eur. J. Immunol. 28 (1998) 1332-1338
128. Salter M.G., and Fern R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438 (2005) 1167-1171
129. Sawcer S., Ban M., Maranian M., Yeo T.W., Compston A., Kirby A., Daly M.J., De Jager P.L., Walsh E., Lander E.S., et al. A high-density screen for linkage in multiple sclerosis. Am. J. Hum. Genet. 77 (2005) 454-467
130. Schneider A., Araujo G.W., Trajkovic K., Herrmann M.M., Merkler D., Mandelkow E.M., Weissert R., and Simons M. Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis. J. Biol. Chem. 279 (2004) 55833-55839
131. Sebat J., Lakshmi B., Troge J., Alexander J., Young J., Lundin P., Maner S., Massa H., Walker M., Chi M., et al. Large-scale copy number polymorphism in the human genome. Science 305 (2004) 525-528
132. Seifert T., Kieseier B.C., Ropele S., Strasser-Fuchs S., Quehenberger F., Fazekas F., and Hartung H.P. TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis. Mult. Scler. 8 (2002) 447-451
133. Seldin M.F., Morii T., Collins-Schramm H.E., Chima B., Kittles R., Criswell L.A., and Li H. Putative ancestral origins of chromosomal segments in individual african americans: implications for admixture mapping. Genome Res. 14 (2004) 1076-1084
134. Setzu A., Lathia J.D., Zhao C., Wells K., Rao M.S., Ffrench-Constant C., and Franklin R.J. Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. Glia 54 (2006) 297-303
135. Sheridan C. Tysabri raises alarm bells on drug class. Nat. Biotechnol. 23 (2005) 397-398
136. Smith K.J. Nitric oxide and axonal pathophysiology. In: Waxman S. (Ed). Multiple Sclerosis as a Neuronal Disease (2005), Elsevier Academic Press, Amsterdam 255-273
137. Smith K.J., Kapoor R., Hall S.M., and Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann. Neurol. 49 (2001) 470-476
138. Smith-Jensen T., Burgoon M.P., Anthony J., Kraus H., Gilden D.H., and Owens G.P. Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response. Neurology 54 (2000) 1227-1232
139. Sotgiu S., Pugliatti M., Sotgiu A., Sanna A., and Rosati G. Does the "hygiene hypothesis" provide an explanation for the high prevalence of multiple sclerosis in Sardinia?. Autoimmunity 36 (2003) 257-260
140. Stefansson H., Sigurdsson E., Steinthirsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T.T., et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71 (2002) 877-892
141. Stefansson H., Helgason A., Thorleifsson G., Steinthorsdottir V., Masson G., Barnard J., Baker A., Jonasdottir A., Ingason A., Gudnadottir V.G., et al. A common inversion under selection in Europeans. Nat. Genet. 37 (2005) 129-137
142. Steinman L., and Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60 (2006) 12-21
143. Steinman L., Martin R., Bernard C., Conlon P., and Oksenberg J.R. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu. Rev. Neurosci. 25 (2002) 491-505
144. Stern J.N., Illes Z., Reddy J., Keskin D.B., Fridkis-Hareli M., Kuchroo V.K., and Strominger J.L. Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 102 (2005) 1620-1625
145. Stratmann T., Martin-Orozco N., Mallet-Designe V., Poirot L., McGavern D., Losyev G., Dobbs C.M., Oldstone M.B., Yoshida K., Kikutani H., et al. Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity. J. Clin. Invest. 112 (2003) 902-914
146. Stuve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., and Yong V.W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40 (1996) 853-863
147. Trapp B.D., Peterson J., Ranshoff R.M., Rudick R., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998) 278-285
148. Vela J.M., Molina-Holgado E., Arevalo-Martin A., Almazan G., and Guaza C. Interleukin-1 regulates proliferation and differentiation of oligodendrocyte progenitor cells. Mol. Cell. Neurosci. 20 (2002) 489-502
149. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., Preiningerova J., Rizzo M., and Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
150. Wallin M.T., Page W.F., and Kurtzke J.F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol. 55 (2004) 65-71
151. Waxman S. Multiple Sclerosis as a Neuronal Disease (2005), Academic Press Inc., U.S., London
152. Willer C.J., Dyment D.A., Sadovnick A.D., Rothwell P.M., Murray T.J., and Ebers G.C. Timing of birth and risk of multiple sclerosis: population based study. BMJ 330 (2005) 120 10.1136/bmj.38301.686030.63 Published online December 7, 2004
153. Windrem M.S., Nunes M.C., Rashbaum W.K., Schwartz T.H., Goodman R.A., McKhann II G., Roy N.S., and Goldman S.A. Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Nat. Med. 10 (2004) 93-97
154. Woodruff R.H., Fruttiger M., Richardson W.D., and Franklin R.J. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol. Cell. Neurosci. 25 (2004) 252-262
155. Wucherpfennig K.W. The structural interactions between T cell receptors and MHC-peptide complexes place physical limits on self-nonself discrimination. Curr. Top. Microbiol. Immunol. 296 (2005) 19-37
156. Yan H., Yuan W., Velculescu V.E., Vogelstein B., and Kinzler K.W. Allelic variation in human gene expression. Science 297 (2002) 1143
157. Yednock T.A., Cannon C., Fritz L., Sanchez-Madrid F., Steinman L., and Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356 (1992) 63-66
158. Zhang Y., Da R.R., Hilgenberg L.G., Tourtellotte W.W., Sobel R.A., Smith M.A., Olek M., Nagra R., Sudhir G., van den Noort S., and Qin Y. Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions. J. Neuroimmunol. 167 (2005) 120-130
159. Ziv Y., Ron N., Butovsky O., Landa G., Sudai E., Greenberg N., Cohen H., Kipnis J., and Schwartz M. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 9 (2006) 268-275